NOVO-111
Solid Tumors (treatment-resistant)
Pre-clinicalActive
Key Facts
About InnovoTEX
InnovoTEX is a private, pre-revenue biotech focused on developing its TEX Core portfolio of macrocycle drug conjugates (MDCs) for solid tumors. The company's platform leverages a clinically validated macrocycle backbone to deliver multi-modal payloads precisely to tumors, aiming to overcome treatment resistance. With its lead asset, NOVO-111, demonstrating promising preclinical results and heading toward the clinic, InnovoTEX is positioning itself in the competitive targeted oncology space. The company is at a critical inflection point, preparing for clinical validation and seeking to expand its intellectual property across multiple indications.
View full company profile